Navegando por Palavras-chave "cisplatino"

Agora exibindo 1 - 1 de 1
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Monitoramento da audição de pacientes expostos à cisplatina
    (ABORL-CCF Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial, 2003-03-01) Garcia, Adriana Pontin [UNIFESP]; Iorio, Maria Cecilia Martinelli [UNIFESP]; Petrilli, Antonio Sergio [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Cisplatin is an antineoplasic drug, which has ototoxicity as a side effect. The goals of this paper were to evaluate the audiological behavior in osteosarcoma patients treated with cisplatin and to verify which evaluation method is the best for early detection of drug induced hearing loss. STUDY DESIGN: Clinical prospective. MATERIAL AND METHOD: 13 patients, that received four cisplatin cycles of 120 mg/m²/cycle divided in two days (60 mg/m²/day), were evaluated prior to start of chemotherapy, prior to each scheduled course and at the end of treatment. It was performed the pure tone audiometry (250 to 18000 Hz) and the transitory and distortion product otoacoustic emission (TOAE and DPOAE). RESULTS: In the mean values, it was observed hearing loss, after 480 mg/m² cumulative cisplatin dosage, beginning at 8 kHz. At the individual values, it was observed that 15,3% had mild to moderate hearing loss beginning at 3kHz, 15,3% beginning at 4 kHz, 15,3% beginning at 6 kHz and 15,3% beginning at 8 kHz. TOAE did not show changes before the audiometry. DPOAE showed smaller amplitude after the cycles of cisplatin, but this change happened together with the audiometry - not prior. CONCLUSION: The high frequency audiometry was more efficient to detect early ototoxicity. TOAE and DPOAE can be used as complement tests. All cisplatin exposed patients showed high frequency hearing loss, 30,6% showed hearing loss in important frequencies (3 and 4 kHz) for speech comprehension.